Shares in Baxter International rose 3.2% on April 16, after the US health care firm said that its first-quarter 2009 profit jumped 19.9% year-on-year to $518.0 million, or $0.83 per share.
During the period, sales fell 2% to $2.82 billion. Analysts polled by Thomson Reuters had predicted profit of $0.83 per share on revenues of $2.87 billion.
According to the Illinois-based firm, its strong downturn-defying performance was partly thanks to robust underlying fundamentals across the portfolio and improved margins, driven by operational leverage and favorable business and product mix.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze